메뉴 건너뛰기




Volumn 15, Issue 7, 2009, Pages 500-505

Pharmacologic treatment of advanced Parkinson's disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors

Author keywords

COMT inhibitors; MAO B inhibitors; Meta analysis; Parkinson's disease

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PLACEBO; RASAGILINE; SELEGILINE; TOLCAPONE;

EID: 67650742878     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.12.007     Document Type: Article
Times cited : (33)

References (21)
  • 1
    • 67650745310 scopus 로고    scopus 로고
    • Ernst ME. Parkinson's Disease. In: Dunsworth T, Richardson M, Cheng J, et al, eds. Pharmacotherapy Self-Assessment Program, 6th ed. Neurology and Psychiatry. Lenexa, KS: American College of Clinical Pharmacy, 2007: 19-33
    • Ernst ME. Parkinson's Disease. In: Dunsworth T, Richardson M, Cheng J, et al, eds. Pharmacotherapy Self-Assessment Program, 6th ed. Neurology and Psychiatry. Lenexa, KS: American College of Clinical Pharmacy, 2007: 19-33
  • 2
    • 33646076457 scopus 로고    scopus 로고
    • Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): a report of the Quality Standards Subcommittee of the American Academy of Neurology
    • Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronset G., Bronte-Stewart H., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): a report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 983-995
    • (2006) Neurology , vol.66 , pp. 983-995
    • Pahwa, R.1    Factor, S.A.2    Lyons, K.E.3    Ondo, W.G.4    Gronset, G.5    Bronte-Stewart, H.6
  • 5
    • 0026776749 scopus 로고
    • Variance imputation for overviews of clinical trials with continuous response
    • Follmann D., Elliott P., Suh I., and Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45 (1992) 769-773
    • (1992) J Clin Epidemiol , vol.45 , pp. 769-773
    • Follmann, D.1    Elliott, P.2    Suh, I.3    Cutler, J.4
  • 6
    • 0030880324 scopus 로고    scopus 로고
    • Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing-off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
    • Baas H., Beiske A.G., Ghika J., Jackson M., Oertel W.H., Poewe W., et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing-off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63 4 (1997) 421-428
    • (1997) J Neurol Neurosurg Psychiatry , vol.63 , Issue.4 , pp. 421-428
    • Baas, H.1    Beiske, A.G.2    Ghika, J.3    Jackson, M.4    Oertel, W.H.5    Poewe, W.6
  • 7
    • 0030833203 scopus 로고    scopus 로고
    • Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment
    • Waters C.H., Kurth M., Bailey P., Shulman L.M., LeWitt P., Dorflinger E., et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 49 (1997) 665-671
    • (1997) Neurology , vol.49 , pp. 665-671
    • Waters, C.H.1    Kurth, M.2    Bailey, P.3    Shulman, L.M.4    LeWitt, P.5    Dorflinger, E.6
  • 8
    • 19244365858 scopus 로고    scopus 로고
    • Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study
    • Fenelon G., Gimenez-Roldan S., Montastruc J.L., Bermejo F., Durif F., Bourdeix I., et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm 110 (2003) 239-251
    • (2003) J Neural Transm , vol.110 , pp. 239-251
    • Fenelon, G.1    Gimenez-Roldan, S.2    Montastruc, J.L.3    Bermejo, F.4    Durif, F.5    Bourdeix, I.6
  • 9
    • 12744272177 scopus 로고    scopus 로고
    • Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations
    • Reichmann H., Boas J., MacMahon D., Myllyla V., Hakala A., Reinikainen K., et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 111 (2005) 21-28
    • (2005) Acta Neurol Scand , vol.111 , pp. 21-28
    • Reichmann, H.1    Boas, J.2    MacMahon, D.3    Myllyla, V.4    Hakala, A.5    Reinikainen, K.6
  • 10
    • 5344247928 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease
    • Olanow C.W., Kieburtz K., Stern M., Watts R., Langston J.W., Guarnieri M., et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 61 (2004) 1563-1568
    • (2004) Arch Neurol , vol.61 , pp. 1563-1568
    • Olanow, C.W.1    Kieburtz, K.2    Stern, M.3    Watts, R.4    Langston, J.W.5    Guarnieri, M.6
  • 11
    • 0041704637 scopus 로고    scopus 로고
    • Entacapone is beneficial in both fluctuating and non-fluctuation patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
    • Brooks D.J., Sagar H., and The UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuation patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74 (2003) 1071-1079
    • (2003) J Neurol Neurosurg Psychiatry , vol.74 , pp. 1071-1079
    • Brooks, D.J.1    Sagar, H.2    The UK-Irish Entacapone Study Group3
  • 12
    • 0035099631 scopus 로고    scopus 로고
    • Gait analysis in advanced Parkinson's disease-effect of levodopa and tolcapone
    • Shan D.E., Lee S.J., Chao L.Y., and Yeh S.I. Gait analysis in advanced Parkinson's disease-effect of levodopa and tolcapone. Can J Neurol Sci 28 (2001) 70-75
    • (2001) Can J Neurol Sci , vol.28 , pp. 70-75
    • Shan, D.E.1    Lee, S.J.2    Chao, L.Y.3    Yeh, S.I.4
  • 13
    • 0036113588 scopus 로고    scopus 로고
    • . Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)
    • Poewe W.H., Deuschl G., Gordin A., Kultalahti E.R., Leinonen M., and the Celomen Study Group. . Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105 (2002) 245-255
    • (2002) Acta Neurol Scand , vol.105 , pp. 245-255
    • Poewe, W.H.1    Deuschl, G.2    Gordin, A.3    Kultalahti, E.R.4    Leinonen, M.5    the Celomen Study Group6
  • 14
    • 15844386001 scopus 로고    scopus 로고
    • Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial
    • Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 (2005) 947-954
    • (2005) Lancet , vol.365 , pp. 947-954
    • Rascol, O.1    Brooks, D.J.2    Melamed, E.3    Oertel, W.4    Poewe, W.5    Stocchi, F.6
  • 15
    • 0034519674 scopus 로고    scopus 로고
    • Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa
    • Rabey J.M., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23 6 (2000) 324-330
    • (2000) Clin Neuropharmacol , vol.23 , Issue.6 , pp. 324-330
    • Rabey, J.M.1    Sagi, I.2    Huberman, M.3    Melamed, E.4    Korczyn, A.5    Giladi, N.6
  • 16
    • 2342426425 scopus 로고    scopus 로고
    • Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study
    • Waters C.H., Sethi K.D., Hauser R.A., Molho E., Bertoni J.M., and The Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19 4 (2004) 426-432
    • (2004) Mov Disord , vol.19 , Issue.4 , pp. 426-432
    • Waters, C.H.1    Sethi, K.D.2    Hauser, R.A.3    Molho, E.4    Bertoni, J.M.5    The Zydis Selegiline Study Group6
  • 18
    • 0036231440 scopus 로고    scopus 로고
    • Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    • Shoulson I., Oakes D., Fahn S., Lang A., Langston W., LeWitt P., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 (2002) 604-612
    • (2002) Ann Neurol , vol.51 , pp. 604-612
    • Shoulson, I.1    Oakes, D.2    Fahn, S.3    Lang, A.4    Langston, W.5    LeWitt, P.6
  • 19
    • 33748320447 scopus 로고    scopus 로고
    • Minimal clinically important change on the unified Parkinson's disease rating scale
    • Schrag A., Sampaio C., Counsell N., and Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 12 8 (2006) 1200-1207
    • (2006) Mov Disord , vol.12 , Issue.8 , pp. 1200-1207
    • Schrag, A.1    Sampaio, C.2    Counsell, N.3    Poewe, W.4
  • 20
    • 33748360763 scopus 로고    scopus 로고
    • Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need
    • Rascol O. Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. Mov Disord 21 (2006) 1059-1061
    • (2006) Mov Disord , vol.21 , pp. 1059-1061
    • Rascol, O.1
  • 21
    • 34547530313 scopus 로고    scopus 로고
    • Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art
    • Rapaport M.H. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry 68 Suppl. 8 (2007) 42-46
    • (2007) J Clin Psychiatry , vol.68 , Issue.SUPPL. 8 , pp. 42-46
    • Rapaport, M.H.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.